UK CAR AND COMMERCIAL VEHICLE MANUFACTURING (data for December and FY 2025)

Hi-res charts available via Dropbox: https://www.dropbox.com/scl/fo/8pskgvu0pspx9u6ueezx7/ADFoByA30j35QgD6fuNPlXE?rlkey=4yq5xdkri6rdzppkgh1eqlmte&st=o1ruv9dj&dl=0 

• Vehicle production down -15.5% in 2025 as 764,715 cars and commercial vehicles leave factories.
• Car output falls -8.0% while CV volumes decline -62.3% as industry restructures amid cyber incident and tariff uncertainties.
• December car growth signals optimism for 2026, driven by new EV models entering production, with opportunity to produce one million vehicles by 2027 if conditions are right.
• Sector calls for government to deliver Industrial and Trade Strategies, to improve manufacturing competitiveness and unlock growth potential.

LONDON, Jan. 29, 2026 /PRNewswire/ — UK vehicle production fell -15.5% in 2025, according to the latest figures published today by the Society of Motor Manufacturers and Traders (SMMT). Factories turned out a total of 764,715 units – 717,371 cars and 47,344 commercial vehicles, with output falling by -8.0% and -62.3% respectively.¹ Volumes were constrained by a number of factors, including a cyber incident stopping production at Britain’s biggest automotive employer; new tariffs on trade across the Atlantic; the consolidation of two CV plants into one; and ongoing restructuring as plants shift to a decarbonised future.

UK global car exports 2025

December saw van, truck, bus and coach volumes decline for a ninth consecutive month, falling -67.7% to 2,281 units, but car production showed signs of recovery, rising 17.7% to 53,003 units and ending four months of decline. Over the year, car production for the UK market fell by -8.2% to 161,545 units while exports declined -7.9% to 555,826 units, accounting for 77.5% of output.

Europe received the majority (56.7%) of vehicles exported, followed by the US (15.0%) and China (6.3%). Exports to each were down, by -3.3%, -18.3% and -12.5% respectively – with shipments to the US impacted by tariff uncertainty earlier in 2025. Turkey and Japan rounded off the UK’s top five global export markets, followed by Canada, Australia, South Korea, Switzerland and UAE.

Production of battery electric (BEV), plug-in hybrid (PHEV) and hybrid (HEV) cars rose by 8.3% to a combined 298,813 units – a record 41.7% share of output. With the start of next generation volume electric car production in Sunderland, and the planned launch of seven new EV models across the UK, output is expected to grow in 2026.

The latest independent production outlook expects overall UK car production to return to growth with output set to rise by more than 10% to some 790,000 units in 2026. Overall light vehicle production is anticipated to reach 824,000 units – with the potential to reach one million units by 2027 provided new model launches stay on track and the right conditions are set.²

Significant public and private investment has already been committed to the UK’s EV transition –with government’s £4 billion DRIVE35 programme launched as part of its Modern Industrial Strategy. Achieving the Strategy’s ambition of UK automotive production reaching over 1.3 million per year by 2035 now depends on the delivery of the commitments set out in the Strategy.

These include measures to drive down the UK’s stubbornly high cost of energy, ensuring the whole sector is eligible for the British Industrial Competitiveness Scheme, support for the UK supply chain, and the creation of a strong and sustainable domestic market. Given that manufacturers – and therefore suppliers – build close to where they sell, the importance of a healthy new vehicle market cannot be overstated.

A forward-looking trade agenda that deepens existing relationships and builds new ones is also fundamental to what is an export-led industry. Europe remains the UK’s biggest automotive export market and the biggest source of imported vehicles and components, so tariff-free trade and market access must be assured, despite a looming change to Rules of Origin requirements agreed under the Brexit deal and increasingly protectionist ‘Made in Europe’ proposals coming from the European Commission.

Furthermore, given the crucial role of US exports – especially to small volume, high value manufacturers – further uncertainty in cross-Atlantic trade has to be avoided while the benefits arising from new deals with South Korea and India must be realised. Above all, the UK must continue to promote the sector’s expertise and capability vigorously to a global audience.

Mike Hawes, SMMT Chief Executive, said, “2025 was the toughest year in a generation for UK vehicle manufacturing. Structural changes, new trade barriers, and a cyber attack that stopped production at one of the UK’s most important manufacturers combined to constrain output, but the outlook for 2026 is one of recovery. The launch of a raft of new, increasingly electric, models and an improving economic outlook in key markets augur well. The key to long term growth, however, is the creation of the right competitive conditions for investment; reduced energy costs; the avoidance of new trade barriers; and a healthy, sustainable domestic market. Government has set out how it will back the sector with its Industrial and Trade strategies, and 2026 must be a year of delivery.”

Notes to editors
1 – ‘Commercial vehicle’ covers vans, trucks, taxis, buses and coaches.
2 – Based on independent production outlook produced by AutoAnalysis in November – cars and light vans only.

SEOUL, South Korea, Jan. 29, 2026 /PRNewswire/ — APR Co., Ltd., a global beauty technology company, announced that cumulative global sales of its beauty device brand, MEDICUBE AGE-R, have surpassed 6 million units, underscoring the company’s accelerating scale and competitiveness in the global home beauty device market.

As of January 2026, cumulative worldwide sales of MEDICUBE AGE-R beauty devices exceeded the 6 million-unit milestone, following the brand’s achievement of 5 million units in the second half of last year. The continued sales momentum highlights MEDICUBE AGE-R’s evolution beyond short-term growth, reflecting a structurally stable and repeat-driven sales base supported by sustained global demand.

MEDICUBE AGE-R has expanded its market presence through a diversified product portfolio designed to address a broad range of individual skincare concerns. Anchored by its flagship “Booster Pro”, the lineup has continued to expand with the introduction of additional devices such as “Ultra Tune 40.68” and “Booster Pro Mini”, reflecting the brand’s focus on accessibility and everyday usability. The devices are designed to be used in combination with MEDICUBE skincare products, allowing consumers to incorporate device-assisted care into their daily at-home skincare routines based on their personal skin needs.

According to APR, the latest milestone was driven by simultaneous growth across international markets and continued advancement of the product lineup. MEDICUBE AGE-R beauty devices have demonstrated strong sales performance in key markets such as the United States and Japan, while expanding into high-growth regions including Greater China and Southeast Asia. More than 60 percent of cumulative device sales are now generated outside Korea, reflecting the brand’s increasing global penetration.

“Booster Pro” continues to serve as MEDICUBE AGE-R’s flagship product, maintaining consistent sales momentum since launch. In October 2025, APR participated as an official sponsor of the APEC Economic Leaders’ Meeting held in Gyeongju, South Korea, where “Booster Pro” was selected as a gift for the spouses of attending heads of state, further reinforcing the brand’s global visibility and product credibility.

Building on this momentum, APR has expanded its compatible device lineup in the South Korean market since July 2025, introducing interchangeable attachments such as the “Booster Vibration Cleanser” and “Booster V Roller.” Designed to enhance convenience and everyday usability around a single core device, these products are scheduled for a phased rollout across international markets. Collectively, the lineup supports a modular at-home skincare approach, allowing consumers to personalize their routines around one core device.

Byung-hoon Kim, Chief Executive Officer of APR Co., Ltd., said: “Surpassing 6 million units in cumulative sales is a meaningful indicator of sustained consumer trust in the MEDICUBE AGE-R brand. By continuing to advance our technology and strengthen portfolio competitiveness, we aim to further expand our leadership in the global home beauty device market.”

About APR Co., Ltd.

APR Co., Ltd. is a global beauty company founded in 2014, focused on integrating advanced beauty technology into everyday skincare routines. With a strong emphasis on efficacy and ease of use, APR develops products that combine skincare expertise with advanced beauty technology.

The company operates a diversified portfolio of beauty brands, including MEDICUBE (skincare), MEDICUBE AGE-R (home beauty devices), and Aprilskin (skincare), addressing a wide range of consumer needs across global markets. Through continuous innovation and consumer-centric development, APR has established a strong presence in the rapidly growing global K-beauty segment.

APR has achieved consistent year-on-year revenue growth and generates the majority of its sales from international markets, reflecting its expanding global footprint. Listed on the Korea Exchange (KOSPI) in 2024, the company reached a market capitalization of over KRW 10 trillion as of January 2026, underscoring its scale and competitiveness as a global beauty player.

About MEDICUBE AGE-R

“MEDICUBE AGE-R” is APR’s home beauty device brand that adapts professional skincare technologies for at-home use, helping consumers achieve effective daily skincare routines with greater convenience.

Since its launch in 2021, “MEDICUBE AGE-R” has recorded strong growth. Cumulative device sales increased from approximately 50,000 units at launch to more than 6 million units as of January 2026, representing more than 100-fold growth over five years.

Through continuous research and development, “MEDICUBE AGE-R” delivers professional-level skincare solutions designed for everyday use at home.

SmartWall ONE™ Relied Upon by Tier-1 Operators to Protect High-Capacity Networks and Enable DDoS Protection-as-a-Service

LONDON, Jan. 29, 2026 /PRNewswire/ — Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today announced two significant wins with Tier-1 telecommunications operators in the Asia-Pacific (APAC) region. The wins reflect growing demand for automated DDoS protection that ensures business continuity, safeguards customer experience, and enables new security services.

“As networks scale, Tier-1 operators are turning to Corero because our DDoS protection is built to perform at the highest levels,” said Carl Herberger, CEO at Corero Network Security. “We help service providers protect massive network capacity, differentiate their services, and deliver always-on security their customers can trust.”

Two Tier-1 telecommunications operators in APAC, both with global operations, are relying on Corero to ensure continuous service availability as their networks scale. One operator is using Corero to protect network capacity of up to 500Gbps, while the other is leveraging Corero to strengthen its security portfolio and deliver DDoS Protection-as-a-Service. Together, these wins help service providers keep customers connected while turning DDoS protection into a differentiated, revenue-generating service.

Across both wins, SmartWall ONE was relied upon to:

• Ensure continuous connectivity and service quality during large-scale DDoS attacks
• Detect and mitigate threats automatically and in real time
• Scale efficiently to support rapid network growth while lowering total cost of ownership
• Enable DDoS Protection-as-a-Service offerings for enterprise and consumer customers

By enabling always-on protection at scale, Corero helps Tier-1 operators keep customers online and secure—even during attack events—while strengthening trust, reducing churn risk, and unlocking new security-driven revenue. These wins reinforce Corero’s expanding footprint in APAC, a strategic growth region where operators are investing in resilience, automation, and differentiated services to support digital economies at scale.

About Corero Network Security
Corero Network Security is a leading provider of DDoS protection solutions, specializing in automatic detection and protection solutions with network visibility, analytics, and reporting tools. Corero’s technology protects against external and internal DDoS threats in complex edge and subscriber environments, ensuring internet service availability. With operational centers in Marlborough, Massachusetts, USA, and Edinburgh, UK, Corero is headquartered in London and listed on the London Stock Exchange’s AIM market (ticker: CNS) and the US OTCQX Market (OTCQX: DDOSF).

MELBOURNE, Australia, Jan. 29, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation of ⁶⁸Ga-PSMA-11) for prostate cancer imaging in Japanese patients. The patient was dosed at Shonan Kamakura General Hospital (SKGH) in Kamakura, Japan.

Illuccix Japan^[1] is a Phase 3 prospective, open-label, multicenter study designed to evaluate the detection efficacy and safety profile of ⁶⁸Ga-PSMA-11 PET/CT^[2] in Japanese patients with biochemically recurrent (BCR) prostate cancer following prior radical prostatectomy. The study will enroll up to 105 Japanese men at 11 sites and data are intended to support a future marketing authorization application for TLX591-Px in Japan.

The primary objective of the study is to compare the sensitivity of ⁶⁸Ga-PSMA-11 PET/CT to conventional imaging (CT and bone scintigraphy) for the detection of metastatic lesions. Secondary objectives include evaluating diagnostic performance for local and distant lesions, safety and tolerability, and the impact of ⁶⁸Ga-PSMA-11 PET/CT on clinical management decisions.

Commencement of the trial augments Telix’s early access and clinical activities in the world’s second-largest market for nuclear medicine. This includes compassionate use for TLX591-Px in Japan^[3], and the Phase 3 ProstACT Global study of TLX591-Tx (lutetium (¹⁷⁷Lu) rosopatamab tetraxetan)^[4] in advanced prostate cancer, which is now open for enrollment^[5].

Dr. David N. Cade, Telix Group Chief Medical Officer, commented, “PSMA-PET^[6] imaging has fundamentally changed how we detect and manage prostate cancer, providing greater accuracy and confidence in treatment planning compared with conventional imaging. Yet, access remains limited in much of Japan, where ⁶⁸Ga-PSMA-11 is not fully validated in the local clinical setting or across all stages of the disease. This milestone, together with Telix’s existing compassionate use supply to address unmet patient need, brings us significantly closer to improving access to gallium-based PSMA-PET and improving outcomes for men living with prostate cancer in Japan.”

About Prostate Cancer in Japan

The Asia Pacific region comprises approximately one-third of the world’s male population and includes many nations whose populations are ageing or increasingly adopting a more affluent, ‘Western-style’ lifestyle, the two main demographic trends driving increasing cancer incidence rates. Consequently, the incidence of prostate cancer is increasing in many parts of the region.

Prostate cancer is the most common cancer in Japanese men with more than 104,000 new diagnoses each year, and the sixth leading cause of cancer-related death with over 14,000 deaths annually^[7].

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

TLX591-Px (Illuccix®), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally, excluding in Japan where use is investigational only.

Visit www.telixpharma.com or jp.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

MELBOURNE, Australia, Jan. 29, 2026 /PRNewswire/ — Amid heightened volatility on the ASX, CFD traders are navigating conditions where blue-chip equities are beginning to exhibit price swings more commonly seen in commodities and indices. Mitrade’s latest strategic outlook, “Financial Markets 2026: Volatility Catalysts in Gold, Silver, Oil, and Blue-Chip Stocks—A CFD Trader’s Outlook“ examines the macroeconomic and cross-asset catalysts driving this repricing and what they may signal for traders positioning into 2026.

The report identifies three interconnected forces reshaping market behaviour: central bank policy uncertainty, geopolitical tensions fuelling demand for safe-haven assets, and competing dynamics within global energy markets—including rising AI infrastructure demand driving industrial inputs. These catalysts are already influencing the ASX today. On 19 January, the ASX 200 dipped 0.3%, with ABC News noting a sharp divergence—tech and bank stocks fell while utilities gained—signalling the broader repricing now affecting blue chip stocks Australia-wide.

“For Australian CFD traders, blue chip stocks offer a more accessible way to engage with market volatility—especially when compared to assets like gold, which often require higher entry capital,” said Elven Jong, CEO of Mitrade Australia. “What we’re seeing is that traditional equities are moving more like macro assets. That shift demands more than just access—it calls for context. Mitrade supports traders with a complete ecosystem that includes risk education, live market insights, and cross-device access to help traders stay connected when conditions shift rapidly.”

Viewed through a global lens, Mitrade’s report reflects broader shifts that are redefining how traders participate in today’s financial markets. Recognised for its commitment to transparency and innovation, Mitrade was named Best Trading Platform Australia 2025 and Best Forex Broker Australia. These accolades underscore the platform’s role in helping traders respond confidently to evolving market conditions.

About Mitrade
Mitrade is an award-winning CFD trading platform founded in Melbourne, trusted by 6M+ traders worldwide. It operates under top-tier financial regulators—Australia’s ASIC (AFSL398528), Cyprus’ CySEC (CIF438/23), the Cayman Islands’ CIMA (SIB1612446), South Africa’s FSCA (54842), and Mauritius’s FSC (GB20025791)—delivering a secure, seamless, and intuitive trading experience.

The platform provides 900+ CFDs on indices, forex, commodities, ETFs, and shares. Mitrade redefines trading with millisecond-execution, razor-thin spreads, robust risk management, and multi-device compatibility.

Trading involves risk. This article is for informational purposes only and does not constitute financial advice, an offer, or a solicitation.

Visit https://www.mitrade.com for more information.

SINGAPORE, Jan. 29, 2026 /PRNewswire/ — Radar Tyres, the flagship brand of Singapore-headquartered Omni United, is proud to announce that it has signed a strategic multi-year partnership with Cricket South Africa (CSA), becoming the Global Partner for the Proteas across all major formats.

As part of the agreement, Radar Tyres will hold Headline sponsorship rights for the Proteas Men’s and Women’s T20 International teams, Associate Partner for the Proteas Men’s and Women’s ODI and Test teams and Headline Partner of the Proteas Under-19 Men’s and Women’s teams.

The partnership delivers extensive on-field and off-field brand visibility, including exclusive logo placement on match and training kits. The Proteas Men revealed their newly branded T20I kit on 27th January in Paarl.

For Radar Tyres, the partnership represents a strategic brand building investment in a globally followed sport. With a growing presence across global markets, Radar continues to leverage high-impact platforms to strengthen brand equity while remaining focused on delivering premium-performance tyres at an accessible price point.

“Becoming the Global Partner of the Proteas marks a significant milestone in Radar Tyres’ global brand journey and reflects our belief in sport as a powerful platform to build brand equity, strengthen dealer support, enhance trust and credibility, and connect with households worldwide. Through this partnership, we are able to engage with cricket fans both locally and globally, while reinforcing Radar Tyres’ as a reliable, performance-driven brand committed to delivering premium-performance tyres at accessible price points.” Said G.S. Sareen, President and CEO, Omni United.

“CSA is extremely proud to partner with Radar Tyres, an organisation that shares our values and commitment to excellence. This partnership is a significant milestone, securing support not only for our senior teams but for our junior teams as well. This partnership reflects our deliberate approach to working with like-minded organisations, guided by a long-term vision of developing the game, supporting our players, and delivering memorable experiences for fans. Radar Tyres’ support also reinforces CSA’s commitment to excellence and inclusion, strengthening our ability to drive high performance across all levels.” Said Pholetsi Moseki, Chief Executive Officer, CSA. 

Radar Tyres are distributed in Australia by National Wheel & Tyre.

Official websites www.omni-united.com and www.radartyres.com

ABOUT RADAR TYRES:
Radar Tyres, the flagship brand of Singapore-headquartered Omni United, is a global tyre brand available in over 80 countries worldwide. The brand believes that everyone has the right to access top-quality, premium tyres at affordable prices. Radar Tyres are test-proven to deliver performance comparable to leading brands but without the premium price tag. Radar Tyres offers a tyres for all seasons and applications, covering passenger cars, SUVs, 4x4s, electric vehicles and commercial vehicles.

SINGAPORE, Jan. 29, 2026 /PRNewswire/ — Radar Tyres, the flagship brand of Singapore-headquartered Omni United, is proud to announce that it has signed a strategic multi-year partnership with Cricket South Africa (CSA), becoming the Global Partner for the Proteas across all major formats.

As part of the agreement, Radar Tyres has Headline sponsorship rights for the Proteas Men’s and Women’s T20 International teams, Associate Partner for the Proteas Men’s and Women’s ODI and Test teams and Headline Partner of the Proteas Under-19 Men’s and Women’s teams.

The partnership delivers extensive on-field and off-field brand visibility, including exclusive logo placement on match and training kits. The Proteas Men revealed their newly branded T20I kit on 27th January in Paarl.

For Radar Tyres, the partnership represents a strategic brand building investment in a globally followed sport. With a growing presence across global markets, Radar continues to leverage high-impact platforms to strengthen brand equity while remaining focused on delivering premium-performance tyres at an accessible price point.

“Becoming the Global Partner of the Proteas marks a significant milestone in Radar Tyres’ global brand journey and reflects our belief in sport as a powerful platform to build brand equity, strengthen dealer support, enhance trust and credibility, and connect with households worldwide. Through this partnership, we are able to engage with cricket fans both locally and globally, while reinforcing Radar Tyres’ position as a reliable, performance-driven brand committed to delivering premium-performance tyres at accessible price points.” Said G.S. Sareen, President and CEO, Omni United.

“CSA is extremely proud to partner with Radar Tyres, an organisation that shares our values and commitment to excellence. This partnership is a significant milestone, securing support not only for our senior teams but for our junior teams as well. This partnership reflects our deliberate approach to working with like-minded organisations, guided by a long-term vision of developing the game, supporting our players, and delivering memorable experiences for fans. Radar Tyres’ support also reinforces CSA’s commitment to excellence and inclusion, strengthening our ability to drive high performance across all levels.” Said Pholetsi Moseki, Chief Executive Officer, CSA.

Radar Tyres are distributed in New Zealand by YHI Limited.

Official websites www.omni-united.com and www.radartyres.com

ABOUT RADAR TYRES:

Radar Tyres, the flagship brand of Singapore-headquartered Omni United, is a global tyre brand available in over 80 countries worldwide. The brand firmly believes that everyone has the right to access top-quality, premium tyres at affordable prices. Radar Tyres are test-proven to deliver performance comparable to leading brands but without the premium price tag. Radar Tyres offers tyres for all seasons and applications, covering passenger cars, SUVs, 4x4s, electric vehicles and commercial vehicles.